Hane FT, Robinson M, Lee BY, Bai O, Leonenko Z, Albert MS. Recent progress in AD research, part 3: diagnosis and treatment. Journal of AD. 2017;57(3):645–65.

Google Scholar 

Pange SS, Patwekar M, Patwekar F, Alghamdi S, et al. A potential notion on AD: nanotechnology as an alternative solution. J Nanomater. 2022;17:2022.

Google Scholar 

Patwekar M, Patwekar F, Shaikh D, Fatema SR, Aher SJ, Sharma R. Receptor-based approaches and therapeutic targets in AD along with role of AI in drug designing: unraveling pathologies and advancing treatment strategies. Appl Chem Eng. 2023;6(3):2338.

Article  Google Scholar 

Salawu FK, Umar JT, Olokoba AB. AD: a review of recent developments. Ann Afr Med. 2011;10(2):73–9.

Article  PubMed  Google Scholar 

Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Diagnosis of early AD: clinical practice in 2021. J Prev AD. 2021;8:371–86.

CAS  Google Scholar 

AëlChetelat G, Baron JC. Early diagnosis of AD: contribution of structural neuroimaging. Neuroimage. 2003;18(2):525–41.

Article  Google Scholar 

Albarqouni L, Arab-Zozani M, Abukmail E, et al. Overdiagnosis and overuse of diagnostic and screening tests in low-income and middle-income countries: a scoping review. BMJ Glob Health. 2022;7(10):e008696.

Article  PubMed  PubMed Central  Google Scholar 

Lichtenberg PA. Misdiagnosis of AD: Case studies in capacity assessment. Clin Gerontol. 2012;35(1):42–56.

Article  Google Scholar 

Dubois B, Hampel H, Feldman HH, et al. Preclinical AD: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292–323.

Article  PubMed  PubMed Central  Google Scholar 

Grand J, Feldman HH. Historical concepts of AD and dementia. Feldman HH (Ed): Atlas of AD. Informa Healthcare, London. 2007. pp1–26.

Alberdi A, Aztiria A, Basarab A. On the early diagnosis of AD from multi-modal signals: a survey. Artif Intell Med. 2016;1(71):1–29.

Article  Google Scholar 

Qiu C, Fratiglioni L, Karp A, Winblad B, Bellander T. Occupational exposure to electromagnetic fields and risk of AD. Epidemiology. 2004;1:687–94.

Article  Google Scholar 

Parvathy Dharshini SA, Sneha NP, Yesudhas D, et al. Exploring plausible therapeutic targets for AD using multi-omics approach, machine learning and docking. Curr Top Med Chem. 2022;22(22):1868–79.

Article  CAS  PubMed  Google Scholar 

Cameron AR, Meyer A, Faverjon C, Mackenzie C. Quantification of the sensitivity of early detection surveillance. Transbound Emerg Dis. 2020;67(6):2532–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allegri RF, Chrem Méndez P, Calandri I, et al. Prognostic value of ATN Alzheimer biomarkers: 60-month follow-up results from the Argentine AD Neuroimaging Initiative. Alzheimer’s Dementia Diagn Assess Dis Monit. 2020;12(1):e12026.

Google Scholar 

Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM. Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β1–42 and τ proteins as Alzheimer disease biomarkers. Clin Chem. 2013;59(6):903–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mayeux R, Schupf N. Blood-based biomarkers for AD: plasma Aβ40 and Aβ42, and genetic variants. Neurobiol Aging. 2011;1(32):S10–9.

Article  Google Scholar 

Shen L, Thompson PM, Potkin SG, et al. Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging Behav. 2014;8:183–207.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008;283(44):29615–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Żekanowski C, Styczyńska M, Pepłońska B, et al. Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset AD in Poland. Exp Neurol. 2003;184(2):991–6.

Article  PubMed  Google Scholar 

Dubois B, von Arnim CA, Burnie N, Bozeat S, Cummings J. Biomarkers in AD: role in early and differential diagnosis and recognition of atypical variants. Alzheimer’s Res Ther. 2023;15(1):175.

Article  Google Scholar 

Ashida S, Koehly LM, Roberts JS, Chen CA, Hiraki S, Green RC. The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study. Eur J Hum Genet. 2010;18(12):1296–301.

Article  PubMed  PubMed Central  Google Scholar 

Howlett J, Hill SM, Ritchie CW, Tom BD. Disease modelling of cognitive outcomes and biomarkers in the European Prevention of Alzheimer’s Dementia Longitudinal Cohort. Front Big Data. 2021;20(4):676168.

Article  Google Scholar 

Chipi E, Salvadori N, Farotti L, Parnetti L. Biomarker-based signature of AD in pre-MCI individuals. Brain Sci. 2019;9(9):213.

Article  PubMed  PubMed Central  Google Scholar 

Mondragóna JD, Sánchez-Catasúsb CA, Mauritsa NM. Tau pathology, neurodegeneration, and neuronal injury biomarker co-occurrence in AT (N) characterized Alzheimer’s and non-AD dementias. Anosognosia of memory deficits in dementia: biomarkers, connectivity, and clinical aspects. 26.

Xu Q, Zhang W, Zuo C. Molecular imaging and targeted therapy in neurology. nuclear medicine in oncology: molecular imaging and target therapy. 2019. pp 257–66.

Mei M, Liu M, Mei Y, Zhao J, Li Y. Sphingolipid metabolism in brain insulin resistance and neurological diseases. Front Endocrinol. 2023. https://doi.org/10.3389/fendo.2023.1243132.

Article  Google Scholar 

Patwekar F, Patwekar M, Lee SW, et al. Antibody-based nanoparticles in Alzheimer’s disease: innovations in diagnosis and therapy. Pathol Res Pract. 2026. https://doi.org/10.1016/j.prp.2026.156421.

Article  PubMed  Google Scholar 

McConathy J, Sheline YI. Imaging biomarkers associated with cognitive decline: a review. Biol Psychiat. 2015;77(8):685–92.

Article  PubMed  Google Scholar 

Betthauser TJ, Koscik RL, Jonaitis EM, Allison SL, Cody KA, Erickson CM, et al. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. Brain. 2020;143(1):320–35.

Article  PubMed  PubMed Central  Google Scholar 

Blom K, Koek HL, Zwartbol MH, van der Graaf Y, Kesseler L, Biessels GJ, et al. Subjective cognitive decline, brain imaging biomarkers, and cognitive functioning in patients with a history of vascular disease: the SMART-Medea study. Neurobiol Aging. 2019;1(84):33–40.

Article  Google Scholar 

Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6(2):67–77.

Article  PubMed  PubMed Central  Google Scholar 

Atiya M, Hyman BT, Albert MS, Killiany R. Structural magnetic resonance imaging in established and prodromal Alzheimer disease: a review. Alzheimer Dis Assoc Disord. 2003;17(3):177–95.

Article  PubMed  Google Scholar 

Shaikh TA, Ali R. Automated atrophy assessment for AD diagnosis from brain MRI images. Magn Reson Imaging. 2019;1(62):167–73.

Article  Google Scholar 

Dona O, Thompson J, Druchok C. Comprehensive review on magnetic resonance imaging in AD. Crit Rev Biomed Eng. 2016;44(7):213–25.

Article  PubMed  Google Scholar 

Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discovery. 2003;2(7):566–80.

Article  CAS  PubMed  Google Scholar 

Ziegler A, Koch A, Krockenberger K, Großhennig A. Personalized medicine using DNA biomarkers: a review. Hum Genet. 2012;131:1627–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aronson JK, Ferner RE. Biomarkers-a general review. Curr Protoc Pharmacol. 2017;76(1):9–23.

Google Scholar 

Feng L, Li J, Zhang R. Current research status of blood biomarkers in AD: Diagnosis and prognosis. Ageing Res Rev. 2021;1(72):101492.

Article  Google Scholar 

Paraskevaidi M, Allsop D, Karim S, Martin FL, Crean S. Diagnostic biomarkers for AD using non-invasive specimens. J Clin Med. 2020;9(6):1673.

Article